Dearfield-based Baxter International announced on Monday that his CEO and board chairman Jose Almeda was retiring, immediately effective-one announcement that came a few days after the company sells its kidney care business for $ 3.7 billion.
Baxter did not say in a news release that why Almeda is now retiring, is immediately effective, but Almida said in release, “With the major elements of our broader strategic change, it leads the company to a new CEO. The right time for. Its next chapter. ,
Almeeda served as the CEO of the company, which has made hospital products since 2016. He will serve in an advisory role in the company by the end of October. In that advisory role, Almeda will receive salary based on an annual rate of $ 650,000, and he will receive a lump sum payment of $ 6.89 million after leaving the company, according to the company, according to a company, a company, a company, a company According to a company, there will be a filing with the Securities and Exchange Commission.
Baxter appointed lead independent director Brent Shefer as chair and interim CEO, while it discovers a new, permanent CEO. Shefer thanked Almida for his service in its release.
“Joe has directed the company through a period of significant development and portfolio repairing, including recently closed sales of its kidney care business, while navigating the market challenges and developing positions,” Shefer Said.
It is reported that the company shut down the global investment firm Carlile for $ 3.7 billion on the sale of its kidney care business. This business is now a new company called Ventive. Although the Venvet is a standalone company, it will remain in the north suburban Chicago, a spokesperson said on Monday.
The sales of the kidney care business boxer were part of a three-dimensional strategy, which was declared by the company in 2023 to strengthen and replace the company. The plan for $ 10.5 billion after the acquisition of a medical equipment and technology company, Hilrom at the end of 2021. Baxter revealed a high -cost in 2022 in 2022 in 2022 of $ 3.1 billion, which means that Hilrom was no longer worth it that Baxter paid for it.
As part of its restructuring after harassed acquisitions, Baxter said in 2023 that he planned to shut down his less than 5% of its workers worldwide.
Baxter has also spent bringing back the production of IV solutions in recent months, after its largest manufacturing plant, in Northern Carolina, in September, Hurricane Helen was damaged by Helen, dangerous to hospitals dependent on those fluids. Baxter said last week that it expects to return to the pre-production level of production at the plant within the first quarter of this year.